SEC Form 4 · accession 0001834021-26-000004
4D Molecular Therapeutics, Inc. · FDMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Kirn
Officer — See Remarks · Director
Period of report
Jul 9, 2026
Accepted (ET)
Jul 14, 2026 · 5:04 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001650648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 9, 2026 | S | 42,608 | $12.8656 | D | 899,877 | D | |
| Common StockF3 | Jul 10, 2026 | S | 15,283 | $12.0107 | D | 884,594 | D | |
| Common StockF4 | Jul 10, 2026 | S | 442 | $12.8355 | D | 884,152 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.
- F2The transaction was executed in multiple trades in prices ranging from $12.68 to $13.23, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3The transaction was executed in multiple trades in prices ranging from $11.575 to $12.49, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4The transaction was executed in multiple trades in prices ranging from $12.82 to $12.88, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Remarks
President and Chief Executive Officer